Hi Wolf - been hanging out. Looks like I missed nothing.
I too picked up a few thou. PRO. I have some interesting information, re Pennsaid, via an UK analyst for PRO (he issued a recent BUY, on PRO, with very little emphasis on the Dimethaid distribution deal. Interesting, that.
He is suggesting that PRO will pick up 2%(yes, that is "two") of the UK market. Using Ms. Keeler's own numbers (the UK market is $375million, that translates into annual sales of $7(andabit) millions.
The question this raises is - why did Ms Keeler select a distributor who is too small to handler distribution for all of EU - and yet whose expected sales will generate annual net cash flows of $1million (using a 15% profit margin).
Isn't this going to create a myriad of management demands on DMX?
I have tried to avoid thinking of the possibilities of difficulties arising at the manufacturing and shipping facility in Canada. But this approach is going to put lots of pressure on everyone at DMX.
eg
-negotiations with how many other distributors;
- orders in, production, shipping out, accounting, and so on.
All of these operations become much more difficult the greater the number of distributors DMX has.
Thoughts? PM me if you can, I returned to 434 new posts. I'll never find your answer next time I log on! TIA Don. |
